ArticleInternational journal of impotence research2025
Application of gelatin sponge (Gelfoam®) as a hemostatic agent in inflatable penile prosthesis implantation.
Article in International journal of impotence research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comment on: Application of gelatin sponge (Gelfoam®) as a hemostatic agent in inflatable penile prosthesis implantation.International journal of impotence research · 2026Article
- Comment on: Application of gelatin sponge (Gelfoam®) as a hemostatic agent in inflatable penile prosthesis implantation.International journal of impotence research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematoma formation is one of the complications of inflatable penile prosthesis implantation (iPP), possibly indicating surgical evacuation, or resulting in infection and removal of the implant. Gelatin Sponge (Gelfoam®, Pfizer, USA) is sterile compressed sponge, used as a hemostatic agent, directly applied to bleeding surfaces. It is water insoluble, but absorbable within 4-6 weeks with minimal scar formation. In this study, we evaluate the use of Gelfoam® for control of hemostasis and minimizing post-operative bleeding in iPP surgery. Fifty-eight patients were enrolled into one of two groups according to their will, documented in the consent form: the Gelatin Sponge (GS) group (n = 22), and the control group (n = 36). Following cylinder insertion, corporotomies were closed by tying the stay sutures. For the GS group, Gelfoam® was applied to the closed corporotomies, pump space and reservoir track. A closed suction drain was inserted for all cases and monitored post-operatively. Mummy wrap was not used to evaluate Gelfoam® independently. Patients were monitored for drain output and complications. The mean drain output was significantly higher in the control group compared to GS group, both for the first 24 h (156.7 cc ± 91.6 cc vs. 45.9 cc ± 36.9 cc, 70.7% difference, p < 0.0001) and 24-48 h (40.7 cc ± 42.4cc vs. 8.6 cc ± 12.6 cc, 78.8% difference, p < 0.0001). No cases of hematoma formation, infection, foreign body reaction, mass formation or hypersensitivity reaction were encountered in the GS group, compared to two cases of hematoma in the control group, one of which dictated drainage (2/36). The findings herein demonstrate the safety and tolerability of Gelfoam® in iPP surgery, as well as its efficacy in minimizing post-operative bleeding.
Identifiers
41131409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.